May 11, 2015 - Boulder, Colorado
The Boulder Peptide Society will host its 9th Annual meeting in Boulder, CO on September 28 to October 1, 2015. Discounted early registration is available until May 31 on the BPS website at:
The Boulder Peptide Symposium once again brings together thought leaders in biotech, pharma, and academic institutions to present current paradigms in peptide therapeutics and to uncover solutions to challenges in peptide drug discovery and development. BPS is pleased to offer a preview of this year's program.
Scientific Sessions: Chemistry and Analytics
Synthesis and bioactivity of glycopeptides and peptide-protein conjugates, Thomas Tolbert, Associate Professor, The University of Kansas
Macrocyclic Organo-Peptide Hybrids as Molecular Scaffolds for Targeting Protein-Protein Interactions, Rudy Fasan, Associate Professor, University of Rochester
Engineering Potent and Selective Analogues of GpTx-1, a Tarantula Venom Peptide Antagonist of the NaV1.7 Sodium Channel, Les Miranda, Director Research, Therapeutic Discovery, Amgen Inc.
Cell-penetrating peptides: current landscape & future applications, Francesca Milletti, Principal Scientist, Roche
Scientific Sessions: Peptides in the Clinic
Injecting Hope: Clinical Development of the NeuVax Vaccine, Elizabeth Mittendorf, Associate Professor, Deputy Chair Research, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
The Clinical Development of Peixganan for the Treatment of Diabetic Foot Infections, Warren Joseph, Consultant, Lower Extremity Infectious Diseasess, Roxborough Memorial Hospital, Philadelphia, PA
Clinical efficacy of a novel P-15 peptide in anterior cervical arthrodesis: A prospective, randomized, controlled, multicenter study, Jerome Connor, Vice President of Research and Development, Cerapedics Inc.
First in class anti-infectives from a novel cationic peptide platform, Deborah O'Neil, Chief Executive & Scientific Officer, NovaBiotics Ltd.
The Clinical Development of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Extensive-stage Small Cell Lung Cancer (SCLC) and Metastatic Renal Cell Carcinoma (mRCC), John R. Stille, Senior Clinical Research Advisor, Eli Lilly and Company
Scientific Sessions: Drug Delivery and Formulations
MICROCOR®: A novel platform transdermal technology for convenient and effective delivery of peptides, Bobby Singh, CTO, Corium International, Inc.
A Chemical Approach to Half-life Extension of Peptides and Proteins, Daniel Santi, President, ProLynx
ELP Biopolymers Significantly Enhance the Pharmacology of Therapeutic Peptides, Jim Ballance, VP Research & Scientific Affairs, PhaseBio Pharmaceuticals, Inc.
Development of a Topical Anti-inflammatory Cell Permeable Peptide for Uveitis, Bruce Littman, CEO, Portage Pharmaceuticals LTD
M. Karen Newell-Rogers, Professor/Consultant, VG Life Sciences/Texas A&M Health Sciences Center
Robin Carmichael, President &COO, Helix BioMedix
Ken Cundy, Chief Scientific Officer, CohBar, Inc.
Michael Sekar, Sr. Director, Formulation Research, Durect Corporation
Andreas Rybka, Head of Chemistry, Nexigen GmbH
Nozer Mehta, Vice President, Biologics, MonoSol Rx
Pascal Deschatelets, Chief Operating Officer, Apellis Pharmaceuticals
Craig Beattie, Chief Scientific Officer, CDG Therapeutics
Jamal Temsamani, Director of Drug Development, Vect-Horus
Fa Liu, Director of Chemistry, Calibrium, LLC
If you wish to be considered for a presentation, please apply at the link:
The 9th Annual meeting will take place at the beautiful St. Julien Hotel and Spa, which has been the venue for this meeting since it’s inception. Boulder Peptide Society is a nonprofit 501(c)(3) organization. More information about the mission of the society and the details of the meeting can be found on the website at www.boulderpeptide.org.